Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan drops patent infringement case

Allergan drops patent infringement case

15th January 2008

Allergan has opted to drop a patent infringement case against a skincare company over a prostaglandin-based ingredient used in a lash-conditioning product.

The lawsuit filed by the pharmaceutical giant against DermaQuest Skin Therapy has now been dismissed without prejudice by certified letter from Allergan.

DermaQuest Skin Therapy DermaLash has now been proven to be free of drugs in its formula and has been dismisses from a patent infringement case involving seven companies.

Sam Dhatt, owner of DermaQuest Skin Therapy, explained: “I promptly submitted the complete ingredient list and all necessary paperwork to Allergan to prove our innocence in this case and asked for prompt dismissal.”

Sold to the professional skincare market since its launch in mid-2007, DermaLash has been inspected by Allergan and contains no ingredients or drugs, such as prostaglandins, that infringe upon the patent for glaucoma treatment Lumigan.

The product is marketed as a drug-free alternative to other lash conditioning products on the market and contains ingredients from naturally-derived sources, such as flower extracts, castor oil, milk protein lactose and bark extract.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.